Low molecular weight heparins were first introduced in the United States in May 1993 as an alternative to currently available anticoagulant therapy. Like standard heparin, these anticoagulants inhibit activation of a number of coagulation enzymes, but low molecular weight heparins have their primary inhibitory effect on factor Xa. A decrease in plasma protein binding by low molecular weight hep...

OBJECTIVE To determine whether an intravenous heparin dosing nomogram based on body weight achieves therapeutic anticoagulation more rapidly than a "standard care" nomogram. DESIGN Randomized controlled trial. SETTING Two community teaching hospitals in Phoenix, Arizona, and Rochester, New York. PARTICIPANTS One hundred fifteen patients requiring intravenous heparin treatment for venous o...

Heparin is an anionic polysaccharide that is widely used as a clinical anticoagulant. This glycosaminoglycan is prepared from animal tissues in metric ton quantities. Animal-sourced heparin is also widely used in the preparation of low molecular weight heparins that are gaining in popularity as a result of their improved pharmacological properties. The recent contamination of pharmaceutical hep...

2112. 13. Lassen, M. R. (2000) The EPHESUS study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH). The prevention of venous thromboembolism (VTE) after elective hip replacement surgery. Blood96(11), Abstract #2109. 14. Erickson, B. (2000) The PENTHIFRA study: comparison of the first synthetic Factor Xa inhibitor with low molecular weight hepari...

The interaction of immunoglobulins with certain acidic polysaccharides was demonstrated by the binding of the sulfated glycans agaropectin and heparin by certain human IgG proteins. Heparin-binding IgG proteins can distinguish between the molecular forms of heparin derived from porcine intestine, bovine lung, and rat skin. The major specificity of these proteins is for native and certain high m...

OBJECTIVES To present a case of heparin induced thrombocytopenia in a patient treated with enoxaparin. METHODS A case of heparin-induced thrombocytopenia was examinated with a detailed platelet count analysis over the time and with detection of platelets antibodies. RESULTS The detection of platelet antobodies and the recovery of platelet count after cessation of enoxaparin strongly support...

We performed a prospective, randomized, double-blind trial in 194 unselected patients to determine the safety and efficacy of low molecular weight heparin (Fragmin) compared with standard heparin as the initial treatment of acute venous thromboembolism. Ninety-eight patients received continuous intravenous heparin, and 96 patients received Fragmin for 5-10 days. Doses were adjusted to maintain ...

Low-molecular-weight heparin (LMWH) is commonly used to treat deep vein thrombosis. The dose is usually based on the patient’s body weight, and for some preparations the manufacturer recommends a daily maximum dose. Unlike the situation for unfractionated heparin, no effective antidote is available for LMWH overdose. Protamine sulphate neutralizes the anticoagulant effect of unfractionated hepa...

T here are no evidence based studies dealing with the incidence of venous sheath related thrombosis and the role of heparin, particularly in the setting of prolonged procedures with multiple lines. The clinical importance of catheter related thrombosis remains undefined in the setting of electrophysiological studies (EPS). We sought to determine the incidence of multiple venous sheath related t...